Document:

Consent to the License Agreement

  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. 
  
 EXHIBIT 10.45 
  
 CONSENT AND AMENDMENT 
  
 This CONSENT AND
AMENDMENT (the “Consent”) is made effective as of September 16, 2002 (the “Consent Date”) by and between THE SLOAN-KETTERING INSTITUTE
FOR CANCER RESEARCH, a non-profit organization having its principal office at 1275 York Ave., New York, NY 10021 (“SKI”) and KOSAN
BIOSCIENCES, INC., a California corporation having a principal place of business at 3832 Bay Center Place, Hayward, California 94545 (“Kosan”). 
  
 WHEREAS, Kosan and SKI are parties to the Research and License Agreement dated August 26, 2000 (the
“License Agreement”). 
  
 WHEREAS, Kosan desires now to enter into an
agreement with Hoffmann-La Roche Inc., a New Jersey corporation, together with F. Hoffmann-La Roche Ltd., a Swiss corporation (collectively, “Roche”), regarding the development and commercialization of an epothilone product (such agreement
with Roche, the “Roche Agreement”) and in connection therewith wishes to grant a sublicense under the License Agreement. 
  
 WHEREAS, SKI desires for Kosan to enter into the Roche Agreement, and the Parties believe that the Roche Agreement will benefit patients by allowing a major pharmaceutical company to
pursue development of a cancer product. 
  
 WHEREAS, the Parties desire to amend
the License Agreement to conform to the Roche Agreement. 
  
 NOW,
THEREFORE, in consideration of the foregoing, the covenants contained herein and other good and valuable consideration the receipt of which is hereby acknowledged, the Parties agree as follows: 

 
 1.    Definitions.    Any initially capitalized terms that are used but not defined herein have
the meanings given such terms when used in all-caps font in the License Agreement. All references to Sections are to sections of this Consent unless explicitly provided to refer to Sections of the License Agreement or the Roche Agreement.

  
 2.    Consent.    SKI consents that Kosan may enter into the Roche Agreement in
the form attached hereto as Appendix A, recognizing that the Roche Agreement includes a sublicense under the License Agreement. 
  
 3.    Harmonizing Amendments.    The following Sections of the License Agreement are hereby amended as follows with respect to the Roche Agreement only: 
  
 (a)    Section 1.25 of the License Agreement is hereby amended such that Net Sales of a given product under the
License Agreement shall be calculated in relation to gross sales of such product in the same way as Net Sales of any Licensed Product under the Roche Agreement, for purposes of determining payments thereunder, are calculated in relation to gross
sales of such Licensed Product. 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES ACT OF 1934, AS AMENDED. 

 

  
 (b)    The restrictions on sublicensing set forth in
Sections 4.5, 4.6, and 4.9 of the License Agreement shall not apply to Roche or its Affiliates under the Roche Agreement, and Roche and its Affiliates shall have the right to grant sublicenses under the Roche Agreement without SKI’s consent.

  
 (c)    For so long as the Roche Agreement is in effect, the obligations imposed on
Kosan by Article 5 of the License Agreement shall be deemed to have been met. 
  
 (d)    The record-keeping and audit-related provisions of the Roche Agreement are agreed to by SKI, and no greater requirements shall be imposed pursuant to Section 7.7 or any other provision of the License
Agreement in relation to any activities under the Roche Agreement, but SKI’s audit rights under the License Agreement with respect to audit of Kosan are and shall not be diminished. 
  
 (e)    Currency conversion of any payments under the Roche Agreement, for purposes of determining payments due under the License Agreement, shall
be as set forth in Section 6.2 of the Roche Agreement, not as set forth in Section 7.10 of or elsewhere in the License Agreement. 
  
 (f)    Section 9.2 of the License Agreement does not apply to the results of research and development work performed pursuant to the Roche Agreement. 
  

(g)    Section 10.3 of the License Agreement does not apply to product recalls of products used or sold under the Roche Agreement.

  
 (h)    Section 18.2.2 is amended such that Roche’s (and its affiliates’ and
sublicensees’) actions, to the extent not in material breach of the Roche Agreement, shall be deemed to be in compliance with any obligations imposed on a sublicensee by the License Agreement, and shall not be deemed in and of themselves to
give rise to a breach of the License Agreement for any purpose, including without limitation Section 18.2.2. Section 18.2.4. is deleted. 
  
 (i)    Article 13 of the License Agreement shall not apply to press releases made by Roche or Kosan or their affiliates or sublicensees under or in relation to the Roche Agreement, except with
respect to the last sentence of such Article of the License Agreement relating to the use of specified names. 
  
 (j)    Kosan’s, Roche’s and their affiliates’ and sublicensees’ activities in compliance with the Roche Agreement shall be deemed to be in compliance with the License Agreement, and the
Roche Agreement shall control for purposes of determining compliance with the Roche Agreement (and therefore also the License Agreement to the extent that the License Agreement imposes obligations with respect to sublicensing and sublicensees). The
foregoing sentence shall not alter the financial terms between Kosan and SKI as set forth in the License Agreement as amended by this Consent. 
  
 4.    Financials. 
  
 (a)    [*] In lieu
of any payments that might otherwise have been required pursuant to Section [*] of the License Agreement in respect of the [*] of the Roche Agreement (but not under any other Sections of the Roche Agreement), Kosan shall
pay to SKI: 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED
IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2
OF THE SECURITIES ACT OF 1934, AS AMENDED. 

 

  
   (i)      [*] 
  
 For the avoidance of doubt, it is agreed and
understood that the payments to be made by Kosan to SKI under this paragraph 4.1(a) are only in consideration of amounts paid or to be paid to Kosan by Roche under [*] of the Roche Agreement, and that such payments under this paragraph
[*] to SKI under [*] of the License Agreement with respect to [*] under other Sections of the Roche Agreement. 
  
 (b)    [*] Any payments Kosan may receive from Roche pursuant to [*] of the Roche Agreement [*] are in [*] Kosan’s
[*] rather than the [*] of a [*] the [*] and so shall [*] to [*] with SKI pursuant to [*] the License Agreement. 
  
 (c)    Royalty Owed.    So long as [*] Kosan under the Roche Agreement
in respect of [*] or otherwise under the sublicense under the License Agreement granted by Kosan to Roche, Kosan shall pay SKI royalties as provided in Article 7 of the License Agreement with respect to such sublicensing proceeds. Once
Kosan no longer receives such sublicensing proceeds from Roche under the Roche Agreement, Kosan shall no longer be obligated to pay SKI any royalty pursuant to the License Agreement on sales of such product(s) by Roche (or its affiliates or
sublicenses). 
  
 5.    Entire Agreement.    This Consent and the License Agreement
collectively set forth the Parties’ entire agreement with respect to the subject matter of the Consent and the License Agreement. This Consent amends the License Agreement. Therefore, to the extent of any conflict between this Consent and the
License Agreement, this Consent shall control. There are no agreements between the Parties with respect to the subject matter of this Consent and the License Agreement other than as set forth in this Consent and the License Agreement as amended by
this Consent. Section 21.1 of the License Agreement shall apply mutatis mutandis to the entire agreement set forth in this Consent and the License Agreement in the same manner as it does to the License Agreement as executed prior to this
Consent. 
  
 6.    Miscellany.    Sections 21.3 – 21.9, 21.14 and 21.15
and Articles 19 and 20 of the License Agreement shall apply to this Consent as if set forth herein in their entireties. 
  
 7.    [*] Recent Application.    SKI and Kosan [*] the application entitled [*] (and noted on [*] of the Roche Agreement as
[*] SKI and Kosan) is [*] and [*] the compounds described and claimed therein [*] SKI and Kosan agree and acknowledge that such [*] execution of this Consent. 

 
 8.    No Relationship.    SKI’s obligations hereunder and pursuant to the License Agreement
are to Kosan only. SKI undertakes no obligation to Roche by this Consent. Roche is not a third-party beneficiary of this Consent. 
  
 IN WITNESS WHEREOF, the Parties have executed this Consent by their duly authorized representatives as of the Consent Date. 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH
THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE
SECURITIES ACT OF 1934, AS AMENDED. 
  

  
 
	 THE SLOAN-KETTERING INSTITUTE
FOR
 CANCER RESEARCH:
 	 	  	 	 KOSAN BIOSCIENCES, INC.: 
 
	 
	 By:
 	 	 /s/    James S. Quirk        
 
	 	  	 	 By:
 	 	 /s/    Michael S. Ostrach        
 

	 
	 Name:
 	 	 James S. Quirk        
 
	 	  	 	 Name:
 	 	 Michael S. Ostrach         
 
	 
	  	 	 Senior Vice President
 	 	  	 	 Title:
 	 	 President
 
	 Title:
 	 	 Research Resources Management         
 
	 	  	 	  	 	  
	 
	 Date:
 	 	 9/19/02
 
	 	  	 	 Date:
 	 	 9/19/02        
 

 
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES ACT OF 1934, AS AMENDED. 

  
 Appendix A- Appendix A corresponds to the document filed as Exhibit 10.43 to Kosan’s 10-Q for the
quarter ended September 30, 2002.  
  
 [ * ] = CERTAIN CONFIDENTIAL INFORMATION
CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND
FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
24B-2 OF THE SECURITIES ACT OF 1934, AS AMENDED.Separation Agreement

  
 EXHIBIT 10.28 
  
 July 25, 2002 
  
 Ronald T. Steckel 
 1115 Abbott Ave. 
 Campbell, CA 95008 
  
 Dear Ron:

  
 This Letter Agreement describes our understanding and agreements regarding the termination of your employment
relationship with RITA Medical Systems, Inc. (the “Company”). By your signature below, you acknowledge and agree with the following: 
  
 1.    Separation Date and Final Salary Payment.    Your employment relationship with the Company will terminate on August 15, 2002 (the
“Separation Date”). As of the Separation Date you will receive all salary due to you as of the Separation Date (including payment for any accrued and unused vacation as of the Separation Date). 
  
 2.    Separation Benefits.    In consideration for your release of claims as set
forth below and your other obligations set forth herein, and provided that you sign the acknowledgement and agreement below signifying your agreement to the terms of this Letter Agreement, including the release of claims, and return the signed
letter to me and all company property in your possession no later than 5:00 p.m. on August 15, 2002, and provided further that you do not exercise your right to revoke this Letter Agreement under Paragraph 6 below, the Company will provide the
following: 
  
         (a)    Salary
Continuation.    You will be entitled to receive continuation of your base salary payable in two equal payments per month for up to six (6) months following the date of termination of your employment. The first payment
shall be made on the first regular payroll date following the end of the Revocation Period described in Paragraph 6 below. This salary continuation is conditioned on your confirmation, to the Company’s satisfaction, that you are actively
seeking full-time employment. In the event you commence full-time employment during the Severance period, the Company’s obligation to pay any severance shall cease at the time of such employment. For purposes of this paragraph, “full-time
employment” shall be defined as at least 35 hours per week of compensated labor, including consulting or other contract work. 
  
                 (b)    Stock Options.    Your stock option vesting will cease as of August 15,
2002. 
  
 3.    Insurance Benefits.    You will continue to
receive the Company’s health insurance benefits (medical, dental and vision) at the Company’s expense through August 31, 2002, which date shall be the “qualifying event” date under the Consolidated Omnibus Budget Reconciliation
Act of 1985, as amended (“COBRA”). Following such date, you have the right to continue the health insurance coverage under COBRA at your own expense. 
  
 4.    Nondisclosure of Confidential and Proprietary Information.    You acknowledge and agree to continue to maintain
the confidentiality of all confidential and proprietary information of the 

  
 Ron Steckel 
 July 25, 2002

 Page 2 
  
 Company as provided by the Confidential Information and
Inventions Assignment Agreement previously entered into between you and the Company, a copy of which is attached hereto as Exhibit A (the “Confidentiality Agreement”), and that such Confidentiality Agreement shall remain in
full force and effect notwithstanding this Letter Agreement. 
  
 5.    Release of
Claims. 
  
         (a)    You acknowledge and
agree that the foregoing consideration represents settlement in full of all outstanding obligations owed to you by the Company. On behalf of yourself, and your heirs, executors, successors and assigns, you agree to hereby fully and forever release
the Company and its officers, directors, employees, investors, shareholders, administrators, predecessor and successor corporations and assigns from any claim, duty, obligation or cause of action relating to any matters of any kind, whether known or
unknown, suspected or unsuspected, that you may possess arising from any omissions, acts or facts that have occurred up until and including the date you sign this Letter Agreement under any and all applicable state and federal laws including,
without limitation: 
  
                 (i)    any and all claims relating to or arising from your employment relationship with the Company and termination
of that relationship; 
  
                 (ii)    any and all claims relating to, or arising from, your right to purchase, or actual purchase of shares of
stock of the Company; 
  
                 (iii)    any and all claims for wrongful discharge of employment; breach of contract, both express and implied;
breach of a covenant of good faith and fair dealing, both express and implied; negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation; negligent or intentional interference with contract or prospective
economic advantage; and defamation; 
  
                 (iv)    any and all claims for violation of any federal, state or municipal statute, including, but not limited to,
Title VII of the Civil Rights Act of 1964, Americans with Disabilities Act, the Age Discrimination in Employment Act of 1967 (up to and including the date you sign this Letter Agreement), the California Fair Employment and Housing Act, and any and
all claims arising out of any other laws and regulations relating to employment or employment discrimination; and 
  
                 (vi)    any and all claims for attorney’s fees and costs. 
  

You agree that the release set forth in this Paragraph 5(a) will be and remain in effect in all respects as a complete and general release as to the matters released.
This release does not extend to any obligations incurred under this Letter Agreement. 
  
         (b)    Except as otherwise provided above in Paragraph 3, you acknowledge and agree that you will not be entitled to participate in any of the Company’s benefit
plans or programs offered to employees of the Company, including, but not limited to, any accrual of vacation, after the Separation Date. 

 
 -2- 

 Ron Steckel 
 July 25, 2002 
 Page 3 
  
 6.    Acknowledgment of Waiver
of Claims under ADEA.    You acknowledge that you are waiving and releasing any rights you may have under the Age Discrimination Act of 1967 (“ADEA”) and that this waiver and release is knowing and voluntary.
You and the Company agree that this waiver and release does not apply to any rights or claims that may arise under ADEA after the date you execute this Letter Agreement. You acknowledge that the consideration given for the waiver and release in this
Letter Agreement is in addition to anything of value to which you were already entitled. You further acknowledge that you have been advised by this writing that (a) you should consult with an attorney prior to executing this Letter Agreement; (b)
you have at least twenty-one (21) days within which to consider this Letter Agreement; (c) you have seven (7) days following your execution of this Letter Agreement to revoke the Letter Agreement (the “Revocation Period”); and (d)
this Letter Agreement shall not be effective until the Revocation Period has expired. 
  
 7.    Civil Code Section 1542.    You and the Company (“we”) each represent to the other that we are not aware of any claim by either of us other than the claims that
are released by Paragraph 5 of this Letter. We each acknowledge that we are familiar with the provisions of California Civil Code Section 1542, which provides as follows: 
  
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM
MUST HAVE MATERIALLY AFFECTED HIS SETTLEMENT WITH THE DEBTOR. 
  
 We, each being aware of such code section, agree to
waive any rights we may have thereunder, as well as under any other statute or common law principles of similar effect. 
  
 8.    Breach of Confidentiality Obligations.    You acknowledge that upon breach of any of the confidentiality provisions contained in Paragraph 4 of this Letter Agreement, the
Company would sustain irreparable harm from such breach, and, therefore, you agree that in addition to any other remedies which the Company may have for any breach of the obligations set forth in this Letter Agreement or the Confidentiality
Agreement, the Company will be entitled to obtain equitable relief, including specific performance and injunctions, restraining you from committing or continuing any such violation of this Letter Agreement or the Confidentiality Agreement.

  
 9.    Non-Disparagement.    The undersigned each
agree to refrain from any disparagement, criticism, defamation, slander of the other, or interference with the contracts and relationships of the other, and the undersigned each represent and warrant that they have not disparaged, criticized,
defamed, slandered the other, or interfered in any manner with the contracts and relationships of the other prior to the Separation Date. 
  
 10.    Arbitration.    The undersigned each agree to attempt to settle all disputes arising in connection with this Agreement through good faith consultation. In
the event no agreement can be reached on such dispute within fifteen (15) days after notification in writing by either party to the other concerning such dispute, the dispute shall be settled by binding arbitration to be conducted in Santa Clara
County, California before the American Arbitration Association under its under its California Employment Dispute Resolution Rules, or by a judge to be mutually agreed upon. The arbitration decision shall be final, conclusive and binding on both
parties and any arbitration award or decision may 

 
 -3- 

 Ron Steckel 
 July 25, 2002 
 Page 4 
  
  
 be entered in any court having
jurisdiction. The undersigned each agree that the prevailing party in any arbitration shall be entitled to injunctive relief in any court of competent jurisdiction to enforce the arbitration award and that the prevailing party in any such proceeding
shall be awarded reasonable attorneys’ fees and costs. This Paragraph 10 shall not apply to the Confidentiality Agreement. The undersigned hereby waive any rights they may have to trial by jury in regard to arbitrable claims. 

 
 11.    Voluntary Execution of Agreement.    You acknowledge that this
Letter Agreement is executed by you voluntarily, with the full intent of releasing all claims against the Company and without any duress or undue influence. You further acknowledge that (i) you have read this entire Letter Agreement, (ii) you
understand the terms and consequences of this Letter Agreement and of the releases it contains, and you have been advised that you may seek legal representation with respect to the matters contained in this Letter Agreement; and (iii) you are fully
aware of the legal and binding effect of this Letter Agreement. 
  
  
 
	 RITA MEDICAL SYSTEMS, INC.
 
	 
	 By:
 	 	 /s/    Barry Cheskin
 

	 Title:
 	 	 President and Chief Executive Officer
 

 
  
 AGREED AND ACKNOWLEDGED: 
 My agreement with the above terms is acknowledged by my signature below. Furthermore, I acknowledge that I have read and understand the foregoing Letter Agreement and that I sign this release of all
claims voluntarily, with full appreciation that I am forever foreclosed from pursuing any of the rights I have waived. 
  
 
	 
	 /s/    RONALD T. STECKEL
 

	 Ronald T. Steckel
 Dated:  July 31, 2002

 

 
 -4- 

  
 EXHIBIT A 
  
 CONFIDENTIALITY AGREEMENT

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00045-of-00352.parquet"}]]